Navigation Links
Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia

rantee that a registrational submission will be made to the FDA based on the data described in this press release or if such registrational submission is made, that it would receive FDA approval. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol- Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

    (1) Robb AS, Forbes RA, Marcus RN, Carson Jr. WH. Efficacy of aripiprazole

    in the treatment of adolescents with schizophrenia. Poster presentation

    NR742 at: annual meeting of the American Psychiatric Association, San

    Diego, California, Wednesday, May 23, 2007, 3:00 p.m. - 5:00 p.m. PST -

    Poster Session 7.


    (2) Findling RL, Nyilas M, Auby P, Mallikaarjun S, McQuade RD, Marcus RN,

    Carson Jr. WH. Tolerability of aripiprazole in the treatment of

    adolescents with schizophrenia. Poster presentation NR741 at: annual

    meeting of the American Psychiatric Association, San Diego, California,

    Wednesday, May 23, 2007, 3:00 p.m. - 5:00 p.m. PST - Poster Session 7.


    (3) IMS Auditrac NGPS: Abilify total monthly retail prescriptions: Data

    accessed 11/2006.

CONTACT: Debra Kaufmann of Otsuka America Pharmaceutical, Inc.,+1-240-683-3568, ; or Hideki Shirai of OtsukaPharmaceutical Co., Ltd., +81-3-3292-0021, ; or David M.Rosen, Communications, +1-609-252-5675, Pager, +1-866-308-4484,, or John Elicker, Investor Relations,+1-212-546-3775, , both of Bristol-Myers Squibb Company debra.kaufmann@otsuka.com




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, ... awarded CSL Behring its 2015 Corporate Leadership Award ... advancing science and improving the care of the bleeding disorders ... CEO and Managing Director, CSL Limited, during the NHF Annual ... on May 21. "The National Hemophilia Foundation is ...
(Date:5/22/2015)... According to a new market ... Instruments, Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020", published by ... reach $736.85 Million by 2020 from $452.36 Million in ... Browse 71 market data Tables and 90 Figures ...
(Date:5/22/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/3rthk2/latest ) ... Regulations on Pharmaceutical International Multi-Center Clinical Trials in ... This is first time in history, Chinese pharmaceutical ... clinical trials of drugs in China ... on March 1, 2015. The guidance provides an ...
Breaking Medicine Technology:National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... achieve undetectable HCV RNA levels following 4 weeks of, treatment with R7128 ... ... - Conference Call Scheduled for 4:00PM ET Today ... announces the preliminary results of a 4-week Phase 1,clinical trial to evaluate ...
... Calif., Jan. 7 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... drug designation from the U.S. Food and Drug ... treatment of recurrent acute,repetitive seizures. In December 2007, ... II clinical trial of JZP-8., JZP-8 is ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate 2Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate 3
(Date:5/23/2015)... Javon Bea Mercy Health System CEO ... Rehabilitation Center, 557 N. Washington St., Janesville, will host ... 5:30-6:30 pm. , The 8-week clinic is lead by ... BSN, who will offer training that encompasses a warm-up, ... and show selection and weekly training plans. , The ...
(Date:5/22/2015)... May 22, 2015 Pioneer Millworks, the ... the forefront of designing with reclaimed wood, introducing their ... Los Angeles, California. Their newest offerings, Vat 35, ... surface and color to America's largest design event. , ... at each show, anxious to see and feel the ...
(Date:5/22/2015)... 2015 Hundreds of federal Xarelto ... individuals who allegedly experienced serious internal bleeding and ... move forward in the U.S. District Court, Eastern ... dated May 4, 2015, the Court has established ... stored information. Among other things, the Order sets ...
(Date:5/22/2015)... 22, 2015 Hands On HealthCare Massage ... 2015, the Annual One Day Sale on Massage ... On HCMT offers drastically reduced certificates one day a year. ... enough sessions, through what used to be the slowest time ... the community as well. This once a year occurrence has ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Coordinating ... a difficult process. Historically providers have not been ... payers. Starting in 2015, Medicare has paved the ... activities. Thanks to the launch of Oculus ... and health systems using the platform will now ...
Breaking Medicine News(10 mins):Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4
... Illuminating the molecular details of normal sperm development, demonstrating ... boy sterile, and pursuing ways to restore fertility have ... University of Texas M. D. Anderson Cancer Center. , ... of Experimental Radiation Oncology, will be inducted as a ...
... for Introducing Key Legislation WASHINGTON, Feb. 13 ... applauded the efforts of Senator Jay Rockefeller (D-WV), ... and Representative Bob Filner, Chairman of the House ... amend Section 7422 of Title 38, expanding the ...
... and tested a synthetic atherosclerosis drug that can reduce ... the side-effect of fatty liver disease (which leads to ... results of this study in mice could lead to ... prevent atherosclerosis. , Targets of this drug, called DMHCA, ...
... to be part of the shared evolutionary past of ... abstractions that apparently takes human math to a higher ... of psychology and neuroscience at Duke University, studies how ... numbers without using language. She,s looking for the brain ...
... of Michigan supports physical activity and nutrition programs for ... 16,600 Michigan children and their local communities will get ... physical activities and to learn to eat healthily, through ... join youngsters like those at Detroit,s Maybury Elementary School ...
... Weight Watchers International, Inc. (NYSE: WTW ... analysts on Thursday, March 5th in New York City. ... overview of the Company,s operations and initiatives.Presentations are expected ... approximately 12:00 p.m. ET. The event will be webcast ...
Cached Medicine News:Health News:Male fertility expert Marvin Meistrich elected AAAS Fellow 2Health News:Male fertility expert Marvin Meistrich elected AAAS Fellow 3Health News:Veterans' Affairs Employee Union Urges Congress to Strengthen Collective Bargaining Rights at VA Hospitals 2Health News:Pre-verbal number sense common to monkeys, babies, college kids 2Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 2Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 3Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 4Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 5Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 6Health News:Weight Watchers to Host Investor Meeting 2
... TST 40 tissue stainer is an "assembly-line ... in histology and cytology laboratories. Programmable continuous ... stains big quantities of slides in short ... in combination with a continuous working principle ...
DS 100, double side an economical, easy-to-use instrument for the automatic staining in histology and cytology....
Cholesterol, Total. An automated analyzer test kits....
For the quantitative determination of total cholesterol in serum....
Medicine Products: